07:32 AM EDT, 07/21/2025 (MT Newswires) -- Oruka Therapeutics ( ORKA ) said Monday the US Food and Drug Administration has cleared its investigational new drug application to start the phase 2a trial of ORKA-001 intended for moderate to severe psoriasis.

The company said it aims to enroll about 80 patients under the trial, with a primary endpoint of PASI 100 or completely clear skin.

Oruka Therapeutics ( ORKA ) said it expects to release efficacy and response duration data from the phase 2a trial in H2 2026.

Shares of Oruka Therapeutics ( ORKA ) were up more than 7% in recent premarket activity Monday.

Price: 15.60, Change: +1.06, Percent Change: +7.29